UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 1 on FORM 10-Q/A
to
FORM 10-Q
x | QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended November 30, 2008
[ | ] | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT |
For the transition period from _________ to __________
Commission file number 000-50720
Raptor Pharmaceuticals Corp. | ||
(Exact name of small business issuer as specified in its charter) | ||
| ||
Delaware |
| 98-0379351 |
(State or other jurisdiction of incorporation or organization) |
| (I.R.S. Employer Identification No.) |
9 Commercial Blvd., Suite 200, Novato, CA 94949 |
(Address of principal executive offices) |
(415) 382-8111 |
(Issuer’s telephone number) |
N/A |
(Former name, former address and former fiscal year, if changed since last report) |
Indicate by check mark whether the registrant: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act, as amended, during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o |
|
|
| Accelerated filer o |
|
| |||
Non-accelerated filer o (Do not check if smaller reporting company) |
| Smaller reporting company [ X ] |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x
There were 60,430,047 shares of the registrant’s common stock, $.001 par value per share outstanding at April 10, 2009.
DOCUMENTS INCORPORATED BY REFERENCE: None.
Explanatory Note:
The Registrant is filing this Amendment No. 1 on Form 10-Q/A (this “Abbreviated Amendment”) to amend its Quarterly Report on Form 10-Q for the quarter ended November 30, 2008 (the “Original Filing”), as filed with the Securities and Exchange Commission on January 13, 2009 (“Original Filing Date”). This Abbreviated Amendment contains (and amends) only the cover page, this explanatory note, the Signature Page and Exhibits 31.1 and 31.2. The purpose of this Abbreviated Amendment is to respond to comments received from the Securities and Exchange Commission and to correct the deficiency in Exhibits 31.1 and 31.2 as originally filed. The Original Filing is hereby superseded and amended only as specially set forth herein and this Abbreviated Amendment does not amend any other information previously filed in the Original Filing. Except as otherwise described herein, the Original Filing continues to speak as of the Original Filing Date.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
RAPTOR PHARMACEUTICALS CORP.
By: /s/ Christopher M. Starr
Christopher M. Starr, Ph.D.
Chief Executive Officer and Director
(Principal Executive Officer)
Date: April 17, 2009
By: /s/ Kim R. Tsuchimoto
Kim R. Tsuchimoto
Chief Financial Officer, Secretary and Treasurer
(Principal Financial Officer and Principal Accounting Officer)
Date: April 17, 2009